COLL Quote, Financials, Valuation and Earnings

Pfizer has a net margin of 6.89% compared to Collegium Pharmaceutical's net margin of 2.31%. Collegium Pharmaceutical's return on equity of 31.53% beat Pfizer's return on equity of 8.91%.

Collegium Pharmaceutical has a consensus price target of $42.80, signalling upside risk potential of 58.4%. On the other hand Pfizer has an analysts' consensus of $30.16 which suggests that it could grow by 38.15%. Given that Collegium Pharmaceutical has higher upside potential than Pfizer, analysts believe Collegium Pharmaceutical is more attractive than Pfizer.

Collegium Pharmaceutical has a beta of 0.762, which suggesting that the stock is 23.775% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.67% to investors and pays a quarterly dividend of $0.43 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $181.9M, which are smaller than Pfizer quarterly revenues of $17.8B. Collegium Pharmaceutical's net income of $12.5M is lower than Pfizer's net income of $410M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 14.53x while Pfizer's PE ratio is 15.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.74x versus 1.97x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 6.89% compared to Collegium Pharmaceutical's net margin of 8.8%. Collegium Pharmaceutical's return on equity of 31.53% beat Supernus Pharmaceuticals's return on equity of 7.61%.

Collegium Pharmaceutical has a consensus price target of $42.80, signalling upside risk potential of 58.4%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 26.34%. Given that Collegium Pharmaceutical has higher upside potential than Supernus Pharmaceuticals, analysts believe Collegium Pharmaceutical is more attractive than Supernus Pharmaceuticals.

Collegium Pharmaceutical has a beta of 0.762, which suggesting that the stock is 23.775% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.882%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $181.9M, which are larger than Supernus Pharmaceuticals quarterly revenues of $174.2M. Collegium Pharmaceutical's net income of $12.5M is lower than Supernus Pharmaceuticals's net income of $15.3M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 14.53x while Supernus Pharmaceuticals's PE ratio is 23.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.74x versus 2.60x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Trevi Therapeutics has a net margin of 6.89% compared to Collegium Pharmaceutical's net margin of --. Collegium Pharmaceutical's return on equity of 31.53% beat Trevi Therapeutics's return on equity of --.

Collegium Pharmaceutical has a consensus price target of $42.80, signalling upside risk potential of 58.4%. On the other hand Trevi Therapeutics has an analysts' consensus of $19.83 which suggests that it could grow by 225.14%. Given that Trevi Therapeutics has higher upside potential than Collegium Pharmaceutical, analysts believe Trevi Therapeutics is more attractive than Collegium Pharmaceutical.

Collegium Pharmaceutical has a beta of 0.762, which suggesting that the stock is 23.775% less volatile than S&P 500. In comparison Trevi Therapeutics has a beta of 0.406, suggesting its less volatile than the S&P 500 by 59.351%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevi Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Trevi Therapeutics pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $181.9M, which are larger than Trevi Therapeutics quarterly revenues of --. Collegium Pharmaceutical's net income of $12.5M is higher than Trevi Therapeutics's net income of -$11.4M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 14.53x while Trevi Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.74x versus -- for Trevi Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 6.89% compared to Collegium Pharmaceutical's net margin of 25.08%. Collegium Pharmaceutical's return on equity of 31.53% beat Zoetis's return on equity of 49.71%.

Collegium Pharmaceutical has a consensus price target of $42.80, signalling upside risk potential of 58.4%. On the other hand Zoetis has an analysts' consensus of $198.93 which suggests that it could grow by 35.55%. Given that Collegium Pharmaceutical has higher upside potential than Zoetis, analysts believe Collegium Pharmaceutical is more attractive than Zoetis.

Collegium Pharmaceutical has a beta of 0.762, which suggesting that the stock is 23.775% less volatile than S&P 500. In comparison Zoetis has a beta of 0.925, suggesting its less volatile than the S&P 500 by 7.51%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.22% to investors and pays a quarterly dividend of $0.50 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Collegium Pharmaceutical quarterly revenues are $181.9M, which are smaller than Zoetis quarterly revenues of $2.3B. Collegium Pharmaceutical's net income of $12.5M is lower than Zoetis's net income of $581M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 14.53x while Zoetis's PE ratio is 26.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.74x versus 7.21x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.